2013 - IXA 2013 Congress


Plenary 2: Hyper Immune

7.2 - DeSens KTx at Cedars-Sinai Medical Center

Presenter: Stanley, Jordan, Tokyo, United States
Authors:


Renal transplantation has long been recognized as the treatment of choice for end-stage renal disease, as it offers improved quality of life and survival.  As a result, the demand for donor kidneys continues to outpace the supply and the ongoing organ shortage crisis persist. Currently, there are more than 96,538 ESRD patients on the deceased donor waiting list, and almost 30,000 new patients register annually, yet fewer than 16,680 kidney transplants were performed in 2011 (based on OPTN data as of March 2013). Unfortunately, the most rapidly growing aspect of kidney transplantation  is the number of patients who need one. As the demand for organs continues to exceed the supply, the number of days spent waiting for a kidney transplant increases exponentially, particularly for patients that are difficult to match secondary to having broadly reactive HLA-specific alloantibodies or difficult to match blood types.

 

The disparity in waiting time experienced by these patients is a by-product of an organ allocation policy adopted in the context of an ongoing organ shortage crisis, which dictates that deceased donor kidneys are allocated to blood type compatible recipients who have a negative complement- dependent cytotoxic crossmatch with their donor. A positive crossmatch (+CMX) indicates the presences of donor specific alloantibodies (DSA) in the serum of a potential recipient, and is associated with a rate of graft loss that exceeds 80%.  In addition, the development of de novo DSAs is associated with poor allograft outcomes long-term.  Alloantibodies develop following exposure to foreign HLA molecules, usually through pregnancy, transfusion, and or transplantation.

 

While local and national efforts to increase organ donation have had some success, the increase is unlikely to provide a large enough donor pool capable of supplying an ABO compatible and a perfectly matched donor for every potential recipient. The scarcity of donor organs has contributed to the disenfranchisement of this group of highly sensitized ESRD patients. Thus, in an effort to optimize organ availability and offer the benefit of renal transplantation to these patients, several transplant centers have developed protocols to overcome sensitization and blood group incompatibilities.

 

As a result of these efforts, it is now possible to perform successful renal transplantation in the presence of blood group incompatibilities and +CMX. Two main desensitization regimens are currently utilized - low-dose intravenous immunoglobulin (IVIG) with plasma exchange (PLEX) and high-dose IVIG. Low-dose IVIG/PLEX has been used successfully in live donor ABO incompatible and +CMX renal  transplantation, while high-dose IVIG has been used to desensitize both living-donor +CMX and highly-HLA sensitized deceased donor (DD) recipients from the waitlist.  High dose IVIG (2gm/kg) alone has been accepted as a reasonable approach to desensitization (-). Rituximab has emerged as an increasingly used agent in desensitization protocols. The B-cell depleting agent is often used in combination with high-dose IVIG and PLEX  + low-dose IVIG protocols.  Here we will discuss the options modification of antibody and B-cells as techniques to improve transplantation of sensitized patients.


You must be logged in to view recordings

Important Disclaimer

By viewing the material on this site you understand and accept that:

  1. The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
  2. The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
  3. The material is solely for educational purposes for qualified health care professionals.
  4. The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
  5. The information cannot be used as a substitute for professional care.
  6. The information does not represent a standard of care.
  7. No physician-patient relationship is being established.

Our Corporate Sponsors

TTS gratefully acknowledges the Corporate Partners whose generous support makes the work of the Society possible:

  • astellas
  • roche
  • sanofi